Antifungal Host Defenses

Paschalis Vergidis, MD, MSc, FECMM, is an Infectious Disease specialist with expertise in infections in the immunocompromised host. He trained in Infectious Diseases at Boston University Medical Center and Transplant Infectious Diseases at Mayo Clinic. In 2012, Dr. Vergidis joined the Transplant Infectious Disease Team at the University of Pittsburgh. In 2016, he relocated to the UK to join the National Aspergillosis Center at the University of Manchester then returned to Mayo Clinic in 2019. He is the Focus Group Chair of the Hematology-Oncology Infectious Disease Service, has directed the COVID-19 Service, and is the Ambulatory Antimicrobial Stewardship lead and Antimicrobial Stewardship Education chair. Dr. Vergidis is the site principal investigator for clinical trials on novel antifungal medications and serves as editor for Microbiology Spectrum. In recognition of his expertise in Medical Mycology, he has been accepted as Fellow of the European Confederation of Medical Mycology.

1. Antifungal Host Defenses and the Risk of Invasive Fungal Infection
2. The IL-17 Pathway and Mucosal Candidiasis
3. The Importance of Spleen Tyrosine Kinase (Syk) in the Immune Response to Candidiasis
4. Dectin-1, Interferon Expression and the Host Immune Response Against Aspergillus fumigatus
5. The Role of Pentraxin-3 in Invasive Aspergillosis
6. Breaches in Antifungal Immunity and Viral-Associated Aspergillosis
7. CARD-9-Dependent Neutrophil Recruitment and Fungal Infection
8. Dendritic Cell Responses to Cryptococcal Infection
9. Development of Glucan Particle-Based Vaccines for Cryptococcosis
10. Tissue Invasion in Mucormycosis and the Role of Coat Protein Homologs
11. TNF-alpha Antagonists and Susceptibility to Histoplasmosis
12. Genetic Predisposition to Disseminated Coccidioidomycosis
13. Anti-CD20 Therapy and Risk of Pneumocystis Pneumonia
14. Bruton Tyrosine Kinase Inhibitors and Risk of Fungal Infection
15. Bioengineering T-cells to Treat Invasive Aspergillus Infection